Form 4 for GH Guardant Health, Inc.
Accepted 2025-07-02 00:00:00 ET · period of report 2025-06-30 · accession 0001576280-25-000213 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-07-02 | 2025-06-30+ | GH | Talasaz AmirAli | Co-CEO, Dir | M - OptEx | $0.00 | +28.8K | 2.00M | +1% | $0 |
| DM | 2025-07-02 | 2025-06-30+ | GH | Talasaz AmirAli | Co-CEO, Dir | F - Tax | $50.93 | -14.6K | 1.98M | -0.7% | -$743.8K |
| DM | 2025-07-02 | 2025-07-01 | GH | Talasaz AmirAli | Co-CEO, Dir | S - Sale+OE | $50.87 | -100.0K | 1.97M | -5% | -$5.09M |
| DM | 2025-07-02 | 2025-06-30+ | GH | Talasaz AmirAli | Co-CEO, Dir | M - OptEx | $0.00 | -28.8K | 144.0K | -17% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-30 | M | A | 4,815 | $0.00 | 2,074,271 | D | — | — | |
| 2 | Common | Common Stock | 2025-06-30 | F | D | 2,441 | $52.04 | 2,071,830 | D | — | — | (F1) These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| 3 | Common | Common Stock | 2025-07-01 | S | D | 72,068 | $50.67 | 1,999,762 | D | — | — | (F2) This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 17, 2024. (F3) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.08 to $51.07 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2025-07-01 | S | D | 27,932 | $51.40 | 1,971,830 | D | — | — | (F2) This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 17, 2024. (F4) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.08 to $51.94 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 5 | Common | Common Stock | 2025-07-01 | M | A | 23,997 | $0.00 | 1,995,827 | D | — | — | |
| 6 | Common | Common Stock | 2025-07-01 | F | D | 12,162 | $50.71 | 1,983,665 | D | — | — | (F1) These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| 7 | Derivative | Restricted Stock Units | 2025-06-30 | M | D | 4,815 | $0.00 | 9,629 | D | $0.00 · — to — | 4,815 Common Stock | (F5) This represents a restricted stock unit award granted on March 12, 2025 that vests in four equal installments on the last day of each calendar quarter, March 31, 2025, June 30, 2025, September 30, 2025, and December 31, 2025. (F6) Not applicable for Restricted Stock Units. |
| 8 | Derivative | Restricted Stock Units | 2025-07-01 | M | D | 23,997 | $0.00 | 143,983 | D | $0.00 · — to — | 23,997 Common Stock | (F7) This restricted stock unit award vested with respect to 1/3 of the shares on January 1, 2025. The remaining shares vest quarterly for the remaining twenty-four months. (F6) Not applicable for Restricted Stock Units. |